Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives

Bioorganic and Medicinal Chemistry

Volumn 13, Issue 4, 2005, Pages 949-961

  Masuda, Naoyuki ^a   Yamamoto, Osamu ^a   Fujii, Masahiro ^a   Ohgami, Tetsuro ^a   Fujiyasu, Jiro ^a   Kontani, Toru ^a   Moritomo, Ayako ^a   Orita, Masaya ^a   Kurihara, Hiroyuki ^a   Koga, Hironobu ^a   Kageyama, Shunji ^a   Ohta, Mitsuaki ^a   Inoue, Hiroshi ^a   Hatta, Toshifumi ^a   Shintani, Masafumi ^a   Suzuki, Hiroshi ^a   Sudo, Kenji ^a   Shimizu, Yasuaki ^a   Kodama, Eiichi ^b   Matsuoka, Masao ^b   Fujiwara, Masatoshi ^c   Yokota, Tomoyuki ^c   Shigeta, Shiro ^d   Baba, Masanori ^e   more..

^a ASTELLAS PHARMA INC   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Rational Drug Design Laboratories   (Japan)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^e KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Non nucleoside HIV 1 reverse transcriptase inhibitor; Thiazolidenebenzenesulfonamide; YM 215389

Indexed keywords

2,5 DICYANO N (5 ISOPROPYL 3,4 DIMETHYL 1,3 THIAZOL 2(3H) YLIDENE)BENZENESULFONAMIDE; 5 BROMO N (4 CHLORO 5 ISOPROPYL 3 METHYL 1,3 THIAZOL 2(3H) YLIDENE) 2 HYDROXYBENZENESULFONAMIDE; ANTIVIRUS AGENT; BENZENESULFONAMIDE DERIVATIVE; EFAVIRENZ; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG; YM 215389; YM 228855;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

CELL LINE; HIV-1; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIAL SENSITIVITY TESTS; REVERSE TRANSCRIPTASE INHIBITORS; SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 19944434039     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.11.045     Document Type: Article

References (15)

1. H. Jonckheere, J. Anné, and E. De Clercq Med. Res. Rev. 20 2000 129
2. R. Esnouf, J. Ran, C. Ross, Y. Jones, D. Stammers, and D. Stuart Nat. Struct. Biol. 2 1995 303
3. D.D. Richman, D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S.A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, and D. Pauletti J. Virol. 68 1994 1660
4. L.T. Bacheler Drug Resist. Updates 2 1999 56
5. S. Staszewski, J. Morales-Ramirez, K.T. Tashima, A. Rachlis, D. Skiest, J. Stanford, R. Stryker, P. Johnson, D.F. Labriola, D. Farina, D.J. Manion, and N.M. Ruiz N. Eng. J. Med. 341 1999 1865
6. L.T. Bacheler, E.D. Anton, P. Kudish, D. Baker, J. Bunville, K. Krakowski, L. Bolling, M. Aujay, X.V. Wang, D. Ellis, M.F. Becker, A.L. Lasut, H.J. George, D.R. Spalding, G. Hollis, and K. Abremski Antimicrob. Agents Chemother. 44 2000 2475
7. N. Masuda, O. Yamamoto, M. Fujii, T. Ohgami, J. Fujiyasu, T. Kontani, A. Moritomo, S. Kageyama, M. Ohta, M. Orita, H. Kurihara, H. Koga, H. Nakahara, H. Inoue, T. Hatta, H. Suzuki, K. Sudo, Y. Shimizu, E. Kodama, M. Matsuoka, M. Fujiwara, T. Yokota, S. Shigeta, and M. Baba Bioorg. Med. Chem. 12 2004 6171 6182
8. W.S. Saari, and J.E. Schwering J. Heterocycl. Chem. 23 1986 1253
9. U. Gerlach, and T. Wollmann Tetrahedron Lett. 33 1992 5499
10. J.F. Fuqiang, and P.N. Confalone Tetrahedron Lett. 41 2000 3271
11. R. Ouedraogo, B. Becker, S. Boverie, F. Somers, M.H. Antoine, B. Pirotte, P. Lebrun, and P. de Tullio Biol. Chem. 383 2002 1759
12. A. Saitoh, H. Iwasaki, A. Nakata, A. Adachi, and H. Shinagawa Microbiol. Immunol. 34 1990 509
13. M. Baba, E. De Clercq, H. Tanaka, M. Ubasawa, H. Takashima, K. Sekiya, I. Nitta, K. Umezu, H. Nakashima, S. Mori, S. Shigeta, R.T. Walker, and T. Miyasaka Proc. Natl. Acad. Sci. U.S.A. 88 1991 2356
14. S. Harada, Y. Koyanagi, and N. Yamamoto Science 229 1985 563
15. R. Pauwels, J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq J. Virol. Methods 20 1988 309